

INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Complete if Known	
				Application Number	New Application <b>204564788</b>
				Filing Date	January 17, 2006
				First Named Inventor	Hummel et al
				Group Art Unit	
				Examiner Name	
				Confirmation No.	
Sheet	1	of	2	Attorney Docket Number	2918-111

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T <sup>6</sup>
		Office <sup>3</sup> Code	Number <sup>4</sup>	Kind <sup>5</sup> (if known)			
/R.N./	1.	WO	2004/035079	A1	The University of Queensland	4/29/04	
	2.	WO	90/09162	A	Abbott Lab	8/23/90	
	3.	WO	92/12168	A	Abbott Lab	7/23/92	
	4.	WO	99/00406	A	The University of Queensland	1/7/99	
	5.	WO	03/033528	A	The University of Queensland	4/24/03	
	6.	WO	03/086448	A	Promics Pty Limited	10/23/03	
Examiner Signature	/Ronald Niebauer/				Date Considered	10/19/2007	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code. <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language translation is attached. AB indicates that only an English language abstract is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Complete if Known	
				Application Number	New Application <b>10/564788</b>
				Filing Date	January 17, 2006
				First Named Inventor	Hummel et al
				Group Art Unit	
				Examiner Name	
				Confirmation No.	
Sheet	2	of	2	Attorney Docket Number	2918-111

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>	
/R.N./	7.	March et al., "Potent cyclic antagonists of the complement C5a receptor on human polymorphonuclear leukocytes. Relationships between structures and activity", MOLECULAR PHARMACOLOGY, vol. 65, no. 4, April 1, 2004, pgs. 868-879.		
	8.	Finch et al., "Low-Molecular-Weight Peptidic and Cyclic Antagonists of the Receptor for the Complement Factor C5a", JOURNAL OF MEDICINAL CHEMISTRY, vol. 42, no. 11, June 3, 1999, pgs. 1965-1974.		
	9.	Wong et al., "Small molecular probes for G-protein-coupled C5a receptors: conformationally constrained antagonists derived from the C terminus of the human plasma protein C5a", JOURNAL OF MEDICINAL CHEMISTRY, vol. 41, no. 18, August 27, 1998, pgs. 3417-3425.		
	10.	Demartino et al., "Arginine 206 of the C5a receptor is critical for ligand recognition and receptor activation by C-terminal hexapeptide analogs", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 270, no. 27, 1995, pgs. 15966-15969.		

/Ronald Niebauer/

10/19/2007